Management of Persistent Avascular Retina in Retinopathy of Prematurity: An International Survey.

IF 1.1 4区医学 Q4 OPHTHALMOLOGY

Ophthalmic surgery, lasers & imaging retina Pub Date : 2026-09-01 Epub Date: 2026-08-17 DOI:10.3928/23258160-20260717-03

Andrea Orpia, Riva Menon, Christina Kilby, Jeong-Yoon Wu, He Eun Forbes, Jason Zhou, Kristin Williams, Moran R Levin, Sripriya Sundararajan, Sarah H Rodriguez, Janet Leath Alexander

{"title":"Management of Persistent Avascular Retina in Retinopathy of Prematurity: An International Survey.","authors":"Andrea Orpia, Riva Menon, Christina Kilby, Jeong-Yoon Wu, He Eun Forbes, Jason Zhou, Kristin Williams, Moran R Levin, Sripriya Sundararajan, Sarah H Rodriguez, Janet Leath Alexander","doi":"10.3928/23258160-20260717-03","DOIUrl":null,"url":null,"abstract":"Background and objective: Indications for laser photocoagulation of persistent avascular retina (PAR) in retinopathy of prematurity (ROP) remain controversial. This study aimed to characterize current clinical practice patterns to inform future studies addressing these discrepancies.Patients and methods: A cross-sectional REDCap (Research Electronic Data Capture) survey was conducted, distributed primarily via email to vitreo-retinal and pediatric ophthalmology fellowship directors. Responses from 106 ROP specialists across six continents were analyzed. The primary outcome was the proportion of respondents recommending laser treatment for PAR following spontaneous ROP regression or intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.Results: Most respondents had completed vitreo-retinal (57%) or pediatric (42%) ophthalmology fellowship training, with many (84%) based in North America. Anti-VEGF was preferred by 80% of respondents as primary ROP treatment for the majority of patients. Laser was more frequently considered for zone II (69%) than zone III (58%) PAR, particularly following anti-VEGF therapy. Following post-anti-VEGF reactivation, laser was recommended in the majority of cases (59%). In spontaneously regressed ROP, 50% of respondents did not routinely recommend laser.Conclusion: Practice patterns for PAR management vary, with greater support for laser in zone II disease and after anti-VEGF therapy.","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"576-583"},"PeriodicalIF":1.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20260717-03","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Indications for laser photocoagulation of persistent avascular retina (PAR) in retinopathy of prematurity (ROP) remain controversial. This study aimed to characterize current clinical practice patterns to inform future studies addressing these discrepancies.

Patients and methods: A cross-sectional REDCap (Research Electronic Data Capture) survey was conducted, distributed primarily via email to vitreo-retinal and pediatric ophthalmology fellowship directors. Responses from 106 ROP specialists across six continents were analyzed. The primary outcome was the proportion of respondents recommending laser treatment for PAR following spontaneous ROP regression or intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.

Results: Most respondents had completed vitreo-retinal (57%) or pediatric (42%) ophthalmology fellowship training, with many (84%) based in North America. Anti-VEGF was preferred by 80% of respondents as primary ROP treatment for the majority of patients. Laser was more frequently considered for zone II (69%) than zone III (58%) PAR, particularly following anti-VEGF therapy. Following post-anti-VEGF reactivation, laser was recommended in the majority of cases (59%). In spontaneously regressed ROP, 50% of respondents did not routinely recommend laser.

Conclusion: Practice patterns for PAR management vary, with greater support for laser in zone II disease and after anti-VEGF therapy.

查看原文本刊更多论文

早产儿视网膜病变持续性无血管视网膜的处理：一项国际调查。

背景与目的：早产儿视网膜病变（ROP）激光光凝治疗持续性无血管视网膜（PAR）的适应症仍存在争议。本研究旨在描述当前的临床实践模式，为解决这些差异的未来研究提供信息。患者和方法：进行了一项横断面REDCap（研究电子数据采集）调查，主要通过电子邮件分发给玻璃体视网膜和儿科眼科研究员主任。我们分析了来自六大洲106位ROP专家的反馈。主要结果是在自发性ROP消退或玻璃体内抗血管内皮生长因子（anti-VEGF）治疗后推荐激光治疗PAR的受访者比例。结果：大多数受访者完成了玻璃体-视网膜（57%）或儿科（42%）眼科研究员培训，其中许多（84%）来自北美。80%的应答者首选抗vegf作为大多数ROP患者的主要治疗方法。II区（69%）比III区（58%）更常考虑激光治疗，特别是在抗vegf治疗后。在抗vegf再激活后，大多数病例（59%）推荐激光治疗。在自发回归ROP中，50%的受访者不建议常规激光治疗。结论：PAR治疗的实践模式各不相同，在II区疾病和抗vegf治疗后更支持激光治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.